Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Purchases $20,622.00 in Stock

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) CMO Noah Rosenberg bought 4,200 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was purchased at an average price of $4.91 per share, with a total value of $20,622.00. Following the completion of the purchase, the chief marketing officer directly owned 6,557 shares in the company, valued at $32,194.87. The trade was a 178.19% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Verrica Pharmaceuticals Stock Performance

NASDAQ VRCA opened at $4.86 on Friday. The stock has a market cap of $83.49 million, a PE ratio of -2.91 and a beta of 1.49. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45. The firm has a 50-day moving average of $5.61 and a 200-day moving average of $5.88. Verrica Pharmaceuticals Inc. has a 52-week low of $3.28 and a 52-week high of $9.82.

Analyst Upgrades and Downgrades

VRCA has been the topic of a number of recent research reports. Zacks Research upgraded Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. HC Wainwright began coverage on Verrica Pharmaceuticals in a report on Tuesday, May 26th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $14.50.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC acquired a new position in shares of Verrica Pharmaceuticals during the 4th quarter worth $5,878,000. Armistice Capital LLC boosted its stake in Verrica Pharmaceuticals by 75.1% in the fourth quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after buying an additional 479,732 shares in the last quarter. Velan Capital Investment Management LP acquired a new stake in Verrica Pharmaceuticals in the fourth quarter valued at about $3,919,000. Boothbay Fund Management LLC bought a new position in Verrica Pharmaceuticals in the third quarter valued at about $1,210,000. Finally, Kalehua Capital Management LLC bought a new position in Verrica Pharmaceuticals in the fourth quarter valued at about $1,959,000. 42.45% of the stock is currently owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.